Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program
SHELTON, CT / ACCESSWIRE / July 8, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development...